In a Phase I clinical trial (NCT04848116), MRX-2843 has shown a favorable safety profile and early signs of anti-tumor activity in patients with relapsed or refractory acute myeloid leukemia (AML) and T-cell acute lymphoblastic leukemia (T-ALL), where aberrant MerTK and FLT3 signaling drive disease progression and therapy resistance. The gene discussed is FLT3; the disease is acute myeloid leukemia.